Amgen sued the board in March 2024, after it declared Enbrel unaffordable for Colorado patients. The drugmaker argued not only that the board’s decision was wrong, but that the law setting up ...
The appeals court ruling blocks Sandoz from producing a biosimilar of Enbrel (etanercept) until 2029, more than thirty years after it was first approved. Sandoz, which is the biosimilars and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback